Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 997 to 1008 of 1008 entries
Sorted by: Best Match Show Resources per page
Pivoting during a pandemic: lessons learned from transitioning a multisite randomized controlled trial to a remote protocol in response to COVID-19.

Translational behavioral medicine

Inverso H, Abadula F, Morrow T, LeStourgeon L, Parmar A, Streisand R, Jaser SS.
PMID: 34427687
Transl Behav Med. 2021 Dec 14;11(12):2187-2193. doi: 10.1093/tbm/ibab103.

THR1VE! is an ongoing multisite randomized clinical trial of a positive psychology intervention designed to treat diabetes distress and improve glycemic outcomes in teens with type 1 diabetes. Due to the COVID-19 pandemic restrictions on clinical research and changes...

Cite
Inverso H, Abadula F, Morrow T, et al. Pivoting during a pandemic: lessons learned from transitioning a multisite randomized controlled trial to a remote protocol in response to COVID-19. Transl Behav Med. 2021;11(12):2187-2193doi: 10.1093/tbm/ibab103.
Inverso, H., Abadula, F., Morrow, T., LeStourgeon, L., Parmar, A., Streisand, R., & Jaser, S. S. (2021). Pivoting during a pandemic: lessons learned from transitioning a multisite randomized controlled trial to a remote protocol in response to COVID-19. Translational behavioral medicine, 11(12), 2187-2193. https://doi.org/10.1093/tbm/ibab103
Inverso, Hailey, et al. "Pivoting during a pandemic: lessons learned from transitioning a multisite randomized controlled trial to a remote protocol in response to COVID-19." Translational behavioral medicine vol. 11,12 (2021): 2187-2193. doi: https://doi.org/10.1093/tbm/ibab103
Inverso H, Abadula F, Morrow T, LeStourgeon L, Parmar A, Streisand R, Jaser SS. Pivoting during a pandemic: lessons learned from transitioning a multisite randomized controlled trial to a remote protocol in response to COVID-19. Transl Behav Med. 2021 Dec 14;11(12):2187-2193. doi: 10.1093/tbm/ibab103. PMID: 34427687; PMCID: PMC8499798.
Copy Download .nbib Format: NLM
Regional Cerebellar Volume Loss Predicts Future Disability in Multiple Sclerosis Patients.

Cerebellum (London, England)

Parmar K, Fonov VS, Naegelin Y, Amann M, Wuerfel J, Collins DL, Gaetano L, Magon S, Sprenger T, Kappos L, Granziera C, Tsagkas C.
PMID: 34417983
Cerebellum. 2021 Aug 21; doi: 10.1007/s12311-021-01312-0. Epub 2021 Aug 21.

Cerebellar symptoms in multiple sclerosis (MS) are well described; however, the exact contribution of cerebellar damage to MS disability has not been fully explored. Longer-term observational periods are necessary to better understand the dynamics of pathological changes within the...

Cite
Parmar K, Fonov VS, Naegelin Y, et al. Regional Cerebellar Volume Loss Predicts Future Disability in Multiple Sclerosis Patients. Cerebellum. 2021;doi: 10.1007/s12311-021-01312-0.
Parmar, K., Fonov, V. S., Naegelin, Y., Amann, M., Wuerfel, J., Collins, D. L., Gaetano, L., Magon, S., Sprenger, T., Kappos, L., Granziera, C., & Tsagkas, C. (2021). Regional Cerebellar Volume Loss Predicts Future Disability in Multiple Sclerosis Patients. Cerebellum (London, England), . https://doi.org/10.1007/s12311-021-01312-0
Parmar, Katrin, et al. "Regional Cerebellar Volume Loss Predicts Future Disability in Multiple Sclerosis Patients." Cerebellum (London, England) vol. (2021). doi: https://doi.org/10.1007/s12311-021-01312-0
Parmar K, Fonov VS, Naegelin Y, Amann M, Wuerfel J, Collins DL, Gaetano L, Magon S, Sprenger T, Kappos L, Granziera C, Tsagkas C. Regional Cerebellar Volume Loss Predicts Future Disability in Multiple Sclerosis Patients. Cerebellum. 2021 Aug 21; doi: 10.1007/s12311-021-01312-0. Epub 2021 Aug 21. PMID: 34417983.
Copy Download .nbib Format: NLM
Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.

Hepatology (Baltimore, Md.)

Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, Kowdley KV, Lai M, Schiff E, Parmar D, Patel P, Chalasani N.
PMID: 33811367
Hepatology. 2021 Oct;74(4):1809-1824. doi: 10.1002/hep.31843. Epub 2021 Jul 19.

BACKGROUND AND AIMS: NAFLD is characterized by insulin resistance and dysregulated lipid and glucose metabolism. Saroglitazar, a dual peroxisome proliferator activated receptor-α/γ agonist, improves insulin sensitivity, and lipid and glycemic parameters. Saroglitazar improved NASH histology in animal studies. In...

Cite
Gawrieh S, Noureddin M, Loo N, et al. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. Hepatology. 2021;74(4):1809-1824doi: 10.1002/hep.31843.
Gawrieh, S., Noureddin, M., Loo, N., Mohseni, R., Awasty, V., Cusi, K., Kowdley, K. V., Lai, M., Schiff, E., Parmar, D., Patel, P., & Chalasani, N. (2021). Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. Hepatology (Baltimore, Md.), 74(4), 1809-1824. https://doi.org/10.1002/hep.31843
Gawrieh, Samer, et al. "Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial." Hepatology (Baltimore, Md.) vol. 74,4 (2021): 1809-1824. doi: https://doi.org/10.1002/hep.31843
Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, Kowdley KV, Lai M, Schiff E, Parmar D, Patel P, Chalasani N. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. Hepatology. 2021 Oct;74(4):1809-1824. doi: 10.1002/hep.31843. Epub 2021 Jul 19. PMID: 33811367.
Copy Download .nbib Format: NLM
Evaluation of cell viability of Human Dental Pulp Stem Cells in Two dimensional and Three dimensional Fibrin Glue Scaffold.

Journal of conservative dentistry : JCD

Parmar A, Ansari NA, Parmar G, Krishnakumar A.
PMID: 33911357
J Conserv Dent. 2020 Sep-Oct;23(5):479-483. doi: 10.4103/JCD.JCD_439_20. Epub 2021 Feb 10.

CONTEXT: Regenerative endodontics uses the concept of tissue engineering to restore the diseased immature tooth, allowing for continued development of the root to a healthy state. For regenerative endodontics, the use of human dental pulp stem cells (HDPSCs) with...

Cite
Parmar A, Ansari NA, Parmar G, et al. Evaluation of cell viability of Human Dental Pulp Stem Cells in Two dimensional and Three dimensional Fibrin Glue Scaffold. J Conserv Dent. 2021;23(5):479-483doi: 10.4103/JCD.JCD_439_20.
Parmar, A., Ansari, N. A., Parmar, G., & Krishnakumar, A. (2020). Evaluation of cell viability of Human Dental Pulp Stem Cells in Two dimensional and Three dimensional Fibrin Glue Scaffold. Journal of conservative dentistry : JCD, 23(5), 479-483. https://doi.org/10.4103/JCD.JCD_439_20
Parmar, Abhishek, et al. "Evaluation of cell viability of Human Dental Pulp Stem Cells in Two dimensional and Three dimensional Fibrin Glue Scaffold." Journal of conservative dentistry : JCD vol. 23,5 (2020): 479-483. doi: https://doi.org/10.4103/JCD.JCD_439_20
Parmar A, Ansari NA, Parmar G, Krishnakumar A. Evaluation of cell viability of Human Dental Pulp Stem Cells in Two dimensional and Three dimensional Fibrin Glue Scaffold. J Conserv Dent. 2020 Sep-Oct;23(5):479-483. doi: 10.4103/JCD.JCD_439_20. Epub 2021 Feb 10. PMID: 33911357; PMCID: PMC8066662.
Copy Download .nbib Format: NLM
Primary signet-ring cell carcinoma of the urinary bladder.

Autopsy & case reports

Benerjee N, Parmar K, Vaiphei K.
PMID: 33968831
Autops Case Rep. 2021 Apr 22;11:e2021264. doi: 10.4322/acr.2021.264.

Primary signet-ring cell carcinoma of the urinary bladder is a rare tumor. The overall incidence is approximately 0.12-0.6% of all urinary bladder malignancies. The majority of the patients present in an advanced stage with a uniformly grim prognosis. As...

Cite
Benerjee N, Parmar K, Vaiphei K. Primary signet-ring cell carcinoma of the urinary bladder. Autops Case Rep. 2021;11:e2021264doi: 10.4322/acr.2021.264.
Benerjee, N., Parmar, K., & Vaiphei, K. (2021). Primary signet-ring cell carcinoma of the urinary bladder. Autopsy & case reports, 11e2021264. https://doi.org/10.4322/acr.2021.264
Benerjee, Nirmalya, et al. "Primary signet-ring cell carcinoma of the urinary bladder." Autopsy & case reports vol. 11 (2021): e2021264. doi: https://doi.org/10.4322/acr.2021.264
Benerjee N, Parmar K, Vaiphei K. Primary signet-ring cell carcinoma of the urinary bladder. Autops Case Rep. 2021 Apr 22;11:e2021264. doi: 10.4322/acr.2021.264. PMID: 33968831; PMCID: PMC8087395.
Copy Download .nbib Format: NLM
Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.

Hepatology (Baltimore, Md.)

Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, Kowdley KV, Lai M, Schiff E, Parmar D, Patel P, Chalasani N.
PMID: 33811367
Hepatology. 2021 Oct;74(4):1809-1824. doi: 10.1002/hep.31843. Epub 2021 Jul 19.

BACKGROUND AND AIMS: NAFLD is characterized by insulin resistance and dysregulated lipid and glucose metabolism. Saroglitazar, a dual peroxisome proliferator activated receptor-α/γ agonist, improves insulin sensitivity, and lipid and glycemic parameters. Saroglitazar improved NASH histology in animal studies. In...

Cite
Gawrieh S, Noureddin M, Loo N, et al. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. Hepatology. 2021;74(4):1809-1824doi: 10.1002/hep.31843.
Gawrieh, S., Noureddin, M., Loo, N., Mohseni, R., Awasty, V., Cusi, K., Kowdley, K. V., Lai, M., Schiff, E., Parmar, D., Patel, P., & Chalasani, N. (2021). Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. Hepatology (Baltimore, Md.), 74(4), 1809-1824. https://doi.org/10.1002/hep.31843
Gawrieh, Samer, et al. "Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial." Hepatology (Baltimore, Md.) vol. 74,4 (2021): 1809-1824. doi: https://doi.org/10.1002/hep.31843
Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, Kowdley KV, Lai M, Schiff E, Parmar D, Patel P, Chalasani N. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. Hepatology. 2021 Oct;74(4):1809-1824. doi: 10.1002/hep.31843. Epub 2021 Jul 19. PMID: 33811367.
Copy Download .nbib Format: NLM
NK and CD8+ T cell phenotypes predict onset and control of CMV viremia after kidney transplant.

JCI insight

Pickering H, Sen S, Arakawa-Hoyt J, Ishiyama K, Sun Y, Parmar R, Ahn RS, Sunga G, Llamas M, Hoffmann A, Deng M, Bunnapradist S, Schaenman JM, Gjertson DW, Rossetti M, Lanier LL, Reed EF.
PMID: 34609965
JCI Insight. 2021 Nov 08;6(21). doi: 10.1172/jci.insight.153175.

CMV causes mostly asymptomatic but lifelong infection. Primary infection or reactivation in immunocompromised individuals can be life-threatening. CMV viremia often occurs in solid organ transplant recipients and associates with decreased graft survival and higher mortality. Furthering understanding of impaired...

Cite
Pickering H, Sen S, Arakawa-Hoyt J, et al. NK and CD8+ T cell phenotypes predict onset and control of CMV viremia after kidney transplant. JCI Insight. 2021;6(21)doi: 10.1172/jci.insight.153175.
Pickering, H., Sen, S., Arakawa-Hoyt, J., Ishiyama, K., Sun, Y., Parmar, R., Ahn, R. S., Sunga, G., Llamas, M., Hoffmann, A., Deng, M., Bunnapradist, S., Schaenman, J. M., Gjertson, D. W., Rossetti, M., Lanier, L. L., Reed, E. F. (2021). NK and CD8+ T cell phenotypes predict onset and control of CMV viremia after kidney transplant. JCI insight, 6(21), . https://doi.org/10.1172/jci.insight.153175
Pickering, Harry, et al. "NK and CD8+ T cell phenotypes predict onset and control of CMV viremia after kidney transplant." JCI insight vol. 6,21 (2021). doi: https://doi.org/10.1172/jci.insight.153175
Pickering H, Sen S, Arakawa-Hoyt J, Ishiyama K, Sun Y, Parmar R, Ahn RS, Sunga G, Llamas M, Hoffmann A, Deng M, Bunnapradist S, Schaenman JM, Gjertson DW, Rossetti M, Lanier LL, Reed EF. NK and CD8+ T cell phenotypes predict onset and control of CMV viremia after kidney transplant. JCI Insight. 2021 Nov 08;6(21). doi: 10.1172/jci.insight.153175. PMID: 34609965.
Copy Download .nbib Format: NLM
Progressive Muscle Relaxation and Guided Imagery in Breast Cancer: A Systematic Review and Meta-analysis of Randomised Controlled Trials.

Indian journal of palliative care

Sinha MK, Barman A, Goyal M, Patra S.
PMID: 34511805
Indian J Palliat Care. 2021 Apr-Jun;27(2):336-344. doi: 10.25259/IJPC_136_21. Epub 2021 Aug 12.

Breast cancer affects the mental well-being of patients who may need psychological support. The combined practice of progressive muscle relaxation (PMR) and guided imagery (GI) is known to improve psychological health. Its effect has been studied in patients with...

Cite
Sinha MK, Barman A, Goyal M, et al. Progressive Muscle Relaxation and Guided Imagery in Breast Cancer: A Systematic Review and Meta-analysis of Randomised Controlled Trials. Indian J Palliat Care. 2021;27(2):336-344doi: 10.25259/IJPC_136_21.
Sinha, M. K., Barman, A., Goyal, M., & Patra, S. (2021). Progressive Muscle Relaxation and Guided Imagery in Breast Cancer: A Systematic Review and Meta-analysis of Randomised Controlled Trials. Indian journal of palliative care, 27(2), 336-344. https://doi.org/10.25259/IJPC_136_21
Sinha, Mithilesh Kumar, et al. "Progressive Muscle Relaxation and Guided Imagery in Breast Cancer: A Systematic Review and Meta-analysis of Randomised Controlled Trials." Indian journal of palliative care vol. 27,2 (2021): 336-344. doi: https://doi.org/10.25259/IJPC_136_21
Sinha MK, Barman A, Goyal M, Patra S. Progressive Muscle Relaxation and Guided Imagery in Breast Cancer: A Systematic Review and Meta-analysis of Randomised Controlled Trials. Indian J Palliat Care. 2021 Apr-Jun;27(2):336-344. doi: 10.25259/IJPC_136_21. Epub 2021 Aug 12. PMID: 34511805; PMCID: PMC8428887.
Copy Download .nbib Format: NLM
Mutational landscape of TRPC6, WT1, LMX1B, APOL1, PTPRO, PMM2, LAMB2 and WT1 genes associated with Steroid resistant nephrotic syndrome.

Molecular biology reports

Thakor JM, Parmar G, Mistry KN, Gang S, Rank DN, Joshi CG.
PMID: 34546508
Mol Biol Rep. 2021 Nov;48(11):7193-7201. doi: 10.1007/s11033-021-06711-4. Epub 2021 Sep 21.

BACKGROUND: Nephrotic syndrome appears as a group of symptoms like proteinuria, edema and hyperlipidemia. Identification of monogenic forms revealed the physiology and pathogenesis of the SRNS.METHODS AND RESULTS: We performed Illumina panel sequencing of seven genes in 90 Indian...

Cite
Thakor JM, Parmar G, Mistry KN, et al. Mutational landscape of TRPC6, WT1, LMX1B, APOL1, PTPRO, PMM2, LAMB2 and WT1 genes associated with Steroid resistant nephrotic syndrome. Mol Biol Rep. 2021;48(11):7193-7201doi: 10.1007/s11033-021-06711-4.
Thakor, J. M., Parmar, G., Mistry, K. N., Gang, S., Rank, D. N., & Joshi, C. G. (2021). Mutational landscape of TRPC6, WT1, LMX1B, APOL1, PTPRO, PMM2, LAMB2 and WT1 genes associated with Steroid resistant nephrotic syndrome. Molecular biology reports, 48(11), 7193-7201. https://doi.org/10.1007/s11033-021-06711-4
Thakor, Jinal M, et al. "Mutational landscape of TRPC6, WT1, LMX1B, APOL1, PTPRO, PMM2, LAMB2 and WT1 genes associated with Steroid resistant nephrotic syndrome." Molecular biology reports vol. 48,11 (2021): 7193-7201. doi: https://doi.org/10.1007/s11033-021-06711-4
Thakor JM, Parmar G, Mistry KN, Gang S, Rank DN, Joshi CG. Mutational landscape of TRPC6, WT1, LMX1B, APOL1, PTPRO, PMM2, LAMB2 and WT1 genes associated with Steroid resistant nephrotic syndrome. Mol Biol Rep. 2021 Nov;48(11):7193-7201. doi: 10.1007/s11033-021-06711-4. Epub 2021 Sep 21. PMID: 34546508.
Copy Download .nbib Format: NLM
Quantification of Cervical Cord Cross-Sectional Area: Which Acquisition, Vertebra Level, and Analysis Software? A Multicenter Repeatability Study on a Traveling Healthy Volunteer.

Frontiers in neurology

Lukas C, Bellenberg B, Prados F, Valsasina P, Parmar K, Brouwer I, Pareto D, Rovira À, Sastre-Garriga J, Gandini Wheeler-Kingshott CAM, Kappos L, Rocca MA, Filippi M, Yiannakas M, Barkhof F, Vrenken H.
PMID: 34421797
Front Neurol. 2021 Aug 04;12:693333. doi: 10.3389/fneur.2021.693333. eCollection 2021.

No abstract available.

Cite
Lukas C, Bellenberg B, Prados F, et al. Quantification of Cervical Cord Cross-Sectional Area: Which Acquisition, Vertebra Level, and Analysis Software? A Multicenter Repeatability Study on a Traveling Healthy Volunteer. Front Neurol. 2021;12:693333doi: 10.3389/fneur.2021.693333.
Lukas, C., Bellenberg, B., Prados, F., Valsasina, P., Parmar, K., Brouwer, I., Pareto, D., Rovira, �. �., Sastre-Garriga, J., Gandini Wheeler-Kingshott, C. A. M., Kappos, L., Rocca, M. A., Filippi, M., Yiannakas, M., Barkhof, F., & Vrenken, H. (2021). Quantification of Cervical Cord Cross-Sectional Area: Which Acquisition, Vertebra Level, and Analysis Software? A Multicenter Repeatability Study on a Traveling Healthy Volunteer. Frontiers in neurology, 12693333. https://doi.org/10.3389/fneur.2021.693333
Lukas, Carsten, et al. "Quantification of Cervical Cord Cross-Sectional Area: Which Acquisition, Vertebra Level, and Analysis Software? A Multicenter Repeatability Study on a Traveling Healthy Volunteer." Frontiers in neurology vol. 12 (2021): 693333. doi: https://doi.org/10.3389/fneur.2021.693333
Lukas C, Bellenberg B, Prados F, Valsasina P, Parmar K, Brouwer I, Pareto D, Rovira À, Sastre-Garriga J, Gandini Wheeler-Kingshott CAM, Kappos L, Rocca MA, Filippi M, Yiannakas M, Barkhof F, Vrenken H. Quantification of Cervical Cord Cross-Sectional Area: Which Acquisition, Vertebra Level, and Analysis Software? A Multicenter Repeatability Study on a Traveling Healthy Volunteer. Front Neurol. 2021 Aug 04;12:693333. doi: 10.3389/fneur.2021.693333. eCollection 2021. PMID: 34421797; PMCID: PMC8371197.
Copy Download .nbib Format: NLM
Immunotherapy and Stereotactic Ablative Radiotherapy for Lung Cancer with Co-existing Interstitial Lung Disease: A Case Report.

Clinical lung cancer

Li GJ, Tan H, Chen H, Parmar A, Louie AV.
PMID: 33714691
Clin Lung Cancer. 2021 Sep;22(5):e734-e737. doi: 10.1016/j.cllc.2021.01.018. Epub 2021 Feb 04.

No abstract available.

Cite
Li GJ, Tan H, Chen H, et al. Immunotherapy and Stereotactic Ablative Radiotherapy for Lung Cancer with Co-existing Interstitial Lung Disease: A Case Report. Clin Lung Cancer. 2021;22(5):e734-e737doi: 10.1016/j.cllc.2021.01.018.
Li, G. J., Tan, H., Chen, H., Parmar, A., & Louie, A. V. (2021). Immunotherapy and Stereotactic Ablative Radiotherapy for Lung Cancer with Co-existing Interstitial Lung Disease: A Case Report. Clinical lung cancer, 22(5), e734-e737. https://doi.org/10.1016/j.cllc.2021.01.018
Li, George J, et al. "Immunotherapy and Stereotactic Ablative Radiotherapy for Lung Cancer with Co-existing Interstitial Lung Disease: A Case Report." Clinical lung cancer vol. 22,5 (2021): e734-e737. doi: https://doi.org/10.1016/j.cllc.2021.01.018
Li GJ, Tan H, Chen H, Parmar A, Louie AV. Immunotherapy and Stereotactic Ablative Radiotherapy for Lung Cancer with Co-existing Interstitial Lung Disease: A Case Report. Clin Lung Cancer. 2021 Sep;22(5):e734-e737. doi: 10.1016/j.cllc.2021.01.018. Epub 2021 Feb 04. PMID: 33714691.
Copy Download .nbib Format: NLM
Pivoting during a pandemic: lessons learned from transitioning a multisite randomized controlled trial to a remote protocol in response to COVID-19.

Translational behavioral medicine

Inverso H, Abadula F, Morrow T, LeStourgeon L, Parmar A, Streisand R, Jaser SS.
PMID: 34427687
Transl Behav Med. 2021 Dec 14;11(12):2187-2193. doi: 10.1093/tbm/ibab103.

THR1VE! is an ongoing multisite randomized clinical trial of a positive psychology intervention designed to treat diabetes distress and improve glycemic outcomes in teens with type 1 diabetes. Due to the COVID-19 pandemic restrictions on clinical research and changes...

Cite
Inverso H, Abadula F, Morrow T, et al. Pivoting during a pandemic: lessons learned from transitioning a multisite randomized controlled trial to a remote protocol in response to COVID-19. Transl Behav Med. 2021;11(12):2187-2193doi: 10.1093/tbm/ibab103.
Inverso, H., Abadula, F., Morrow, T., LeStourgeon, L., Parmar, A., Streisand, R., & Jaser, S. S. (2021). Pivoting during a pandemic: lessons learned from transitioning a multisite randomized controlled trial to a remote protocol in response to COVID-19. Translational behavioral medicine, 11(12), 2187-2193. https://doi.org/10.1093/tbm/ibab103
Inverso, Hailey, et al. "Pivoting during a pandemic: lessons learned from transitioning a multisite randomized controlled trial to a remote protocol in response to COVID-19." Translational behavioral medicine vol. 11,12 (2021): 2187-2193. doi: https://doi.org/10.1093/tbm/ibab103
Inverso H, Abadula F, Morrow T, LeStourgeon L, Parmar A, Streisand R, Jaser SS. Pivoting during a pandemic: lessons learned from transitioning a multisite randomized controlled trial to a remote protocol in response to COVID-19. Transl Behav Med. 2021 Dec 14;11(12):2187-2193. doi: 10.1093/tbm/ibab103. PMID: 34427687; PMCID: PMC8499798.
Copy Download .nbib Format: NLM
Showing 997 to 1008 of 1008 entries